-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, and Platinum Pharmaceutical-B (02142.HK) announced that the company's partner Spruce Biosciences Inc. (NASDAQ: SPRB) (Spruce) has split its CRHX-101 (also known as HBM9013/ HAT001/SPR-202) project into Adrenyx Biosciences, Inc. (Adrenyx), a newly founded subsidiary of Spruce, and Adrenyx It is expected to be listed on NASDAQ in the first half of 2027. Upon completion of the plan to distribute Adrenyx common shares in proportion to Spruce shareholders, and Platinum Pharmaceuticals are expected to hold shares in Spruce and Adrenyx at the same time. CRHX-101 is a monoclonal antibody designed and developed to treat congenital adrenal hyperplasia. AdrenyX plans to submit a new drug clinical trial application for CRHX-101 to the US Food and Drug Administration, and then begin clinical development.

Zhitongcaijing·11/18/2026 00:17:09
Listen to the news
Zhitong Financial App News, and Platinum Pharmaceutical-B (02142.HK) announced that the company's partner Spruce Biosciences Inc. (NASDAQ: SPRB) (Spruce) has split its CRHX-101 (also known as HBM9013/ HAT001/SPR-202) project into Adrenyx Biosciences, Inc. (Adrenyx), a newly founded subsidiary of Spruce, and Adrenyx It is expected to be listed on NASDAQ in the first half of 2027. Upon completion of the plan to distribute Adrenyx common shares in proportion to Spruce shareholders, and Platinum Pharmaceuticals are expected to hold shares in Spruce and Adrenyx at the same time. CRHX-101 is a monoclonal antibody designed and developed to treat congenital adrenal hyperplasia. AdrenyX plans to submit a new drug clinical trial application for CRHX-101 to the US Food and Drug Administration, and then begin clinical development.